Link to “Public Notice” Published in Business Standard

In compliance with the recent GST amendments effective from 22.09.2025, the Maximum Retail Price (MRP)of certain pharmaceutical products and medical devices manufactured and marketed by us has been revised.

• For stocks already released into the market before 22.09.2025, dealers/stockists/retailers are required to display the Revised/Supplementary Price List at their
  premises for the information of consumers.
• For stocks manufactured and released on or after 22.09.2025, the revised MRP is affixed/printed directly on the labels/packages.

Consumers are hereby advised to ensure that they are billed as per the Revised/Supplementary Price List or the revised MRP printed on the pack, as applicable.

Any sale above the revised MRP amounts to overcharging, which is an unfair trade practice and is punishable under applicable laws. Neither Brawn Biotech Limited (authorized distributor of Brawn Laboratories Limited) nor Brawn Laboratories Limited shall be liable for any violation or overcharging by dealers/stockists/retailers.

Link to “Public Notice” Published in Business Standard